NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis $7.64 +0.14 (+1.87%) As of 11:55 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Daxor Stock (NASDAQ:DXR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daxor alerts:Sign Up Key Stats Today's Range$7.64▼$7.7650-Day Range$7.05▼$8.5052-Week Range$6.55▼$10.00Volume934 shsAverage Volume6,146 shsMarket Capitalization$36.95 millionP/E RatioN/ADividend YieldN/APrice Target$24.75Consensus RatingBuy Company OverviewDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Read More… Daxor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreDXR MarketRank™: Daxor scored higher than 66% of companies evaluated by MarketBeat, and ranked 349th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDaxor has received no research coverage in the past 90 days.Read more about Daxor's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.60% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthWeak Dividend YieldDaxor does not currently pay a dividend.Dividend GrowthDaxor does not have a long track record of dividend growth.Read more about Daxor's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.60% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.7 / 5News Sentiment0.08 News SentimentDaxor has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Daxor this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Daxor insiders have not sold or bought any company stock.Percentage Held by Insiders59.00% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.34% of the stock of Daxor is held by institutions.Read more about Daxor's insider trading history. Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address DXR Stock News HeadlinesDaxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024March 4 at 4:55 PM | globenewswire.comDaxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025March 4 at 3:53 PM | globenewswire.com(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plans to overhaul the federal government with President Trump… I want to tell you about his REAL goal.March 6, 2025 | Paradigm Press (Ad)Daxor reports increase in NAV to $7.25 per shareMarch 4 at 9:07 AM | markets.businessinsider.comDaxor issues letter to shareholdersMarch 4 at 9:07 AM | markets.businessinsider.comDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersMarch 4 at 9:00 AM | globenewswire.comDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersMarch 4 at 8:05 AM | globenewswire.comDaxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023March 4 at 8:00 AM | globenewswire.comSee More Headlines DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed this year? Daxor's stock was trading at $7.69 at the beginning of 2025. Since then, DXR stock has decreased by 0.7% and is now trading at $7.64. View the best growth stocks for 2025 here. Who are Daxor's major shareholders? Top institutional shareholders of Daxor include Renaissance Technologies LLC (0.57%). Insiders that own company stock include Michael Richard Feldschuh and Robert J Michel. View institutional ownership trends. How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and Company Calendar Today3/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DXR CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$24.75 High Stock Price Target$24.75 Low Stock Price Target$24.75 Potential Upside/Downside+224.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.61 million Price / Sales14.18 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,837,000Free Float1,983,000Market Cap$36.95 million OptionableNot Optionable Beta-0.53 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DXR) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.